^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    arzoxifene (LY353381)

    i
    Associations
    News

    Trials

    Company:
    Eli Lilly
    Drug class:
    Selective estrogen receptor modulator
    Related drugs:
    Associations
    News

    Trials

    Apply
    LY353381 in Preventing Breast Cancer in Women With Hyperplasia (NCT00005879)
    Phase 2
    University of Kansas Medical Center
    Completed
    Last update posted :
    05/30/2017
    Initiation :
    08/01/2000
    Primary completion :
    07/01/2008
    Completion :
    07/01/2008
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    arzoxifene (LY353381)
    Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer (NCT00005886)
    Phase 1
    University of Kansas Medical Center
    Completed
    Last update posted :
    01/13/2017
    Initiation :
    07/01/2000
    Primary completion :
    08/01/2002
    Completion :
    08/01/2002
    PGR
    |
    ER positive + PGR positive • PGR positive
    |
    tamoxifen • Soltamox (tamoxifen citrate) • arzoxifene (LY353381)